Gebhart R J, Duma R J, Patterson P M, Bagett J W, Williams D S
J Antimicrob Chemother. 1985 Feb;15(2):233-8. doi: 10.1093/jac/15.2.233.
Imipenem (N-Formimidoyl thienamycin) (MK-0787) is a new beta-lactam carbapenem antibiotic. When it is combined with the renal dipeptidase inhibitor cilastatin (MK-0791) the combination is known as primaxin. In this study 28 adult patients (24 males and 4 females) with acute bacterial pneumonia were treated with primaxin. Twenty-one patients were evaluable and 20 (95%) were clinically cured of their pneumonia. Bacteriological cures were demonstrated in 84% of the cases. One patient with a susceptible Pseudomonas aeruginosa failed. Major complications or toxic reactions included antibiotic associated diarrhoea in one patient; hypotension in one patient; increased grand mal seizures in one patient and elevated liver function studies in one patient. Results of this study suggest that primaxin will be useful in the treatment of a variety of serious Gram-positive and Gram-negative pneumonias. The true incidence of possible toxic reactions with this drug is not known at this time and awaits further experience.
亚胺培南(N-甲酰亚胺硫霉素)(MK-0787)是一种新型β-内酰胺类碳青霉烯抗生素。当它与肾二肽酶抑制剂西司他丁(MK-0791)联合使用时,该组合被称为泰能。在本研究中,28例成年急性细菌性肺炎患者(24例男性和4例女性)接受了泰能治疗。21例患者可评估,其中20例(95%)肺炎临床治愈。84%的病例显示细菌学治愈。1例对铜绿假单胞菌敏感的患者治疗失败。主要并发症或毒性反应包括1例患者出现抗生素相关性腹泻;1例患者出现低血压;1例患者癫痫大发作增加;1例患者肝功能检查结果升高。本研究结果表明,泰能将有助于治疗各种严重的革兰氏阳性和革兰氏阴性肺炎。目前尚不清楚该药物可能发生的毒性反应的真实发生率,有待进一步经验积累。